Hotgen Biotech

Hotgen Biotech, formally Beijing Hotgen Biotech Co., Ltd., is a Chinese biotechnology and medical-diagnostics company founded in Beijing in 2005. Its principal business is the research, development, manufacture, and sale of in-vitro diagnostic reagents and related instruments. The company’s portfolio covers immunodiagnostics and molecular diagnostics, placing it within the clinical laboratory and point-of-care testing sectors rather than the consumer healthcare market generally. The company became a publicly traded enterprise in September 2019, when it was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange under ticker 688068.SH. Its public-market profile and technology focus have made it one of the better-known Chinese listed companies in the in-vitro diagnostics field. Hotgen was also formerly included in the STAR 50 Index, an index associated with leading companies listed on the Shanghai Science and Technology Innovation Board. Hotgen’s international visibility increased substantially during the COVID-19 pandemic. It developed and commercialized 2019-nCoV antigen diagnostic products, including rapid antigen test kits intended for home or near-patient use. Some of these products obtained European CE certification, and the company’s COVID-19 antigen self-test products gained market access in Germany in early 2021. In March 2022, its rapid-antigen-test products were approved by China’s National Medical Products Administration. Later in 2022, the United States Food and Drug Administration granted an Emergency Use Authorization for the Hotgen COVID-19 Antigen Home Test. The company’s pandemic products were also used in public-health distribution. In 2022, Hotgen rapid antigen test kits were distributed free of charge to members of the public by the Hong Kong government. The pandemic period brought a major temporary expansion in demand for diagnostic testing and was associated with a sharp increase in Hotgen’s reported profitability in 2021. The company has also maintained an overseas presence, including activities or market presences in the United Kingdom, France, and Germany. Beyond COVID-19 testing, Hotgen’s broader business remains centered on diagnostic reagents and instruments for laboratory and clinical applications. Its business model combines proprietary diagnostic technologies, manufacturing, regulatory approvals, and sales through domestic and international channels. The company continues to present itself as a high-technology enterprise in the in-vitro diagnostics sector. Its participation in the MEDICA medical-technology trade fair in Düsseldorf in November 2023 reflected its continuing effort to engage international professional and distribution markets.

Hotgen Biotech was established in Beijing in 2005 by Lin Changqing. From its foundation, the company developed around in-vitro diagnostics, a field that supplies reagents and instruments used to analyze biological samples outside the human body. Its activities have included immunodiagnostic and molecular-diagnostic technologies, as well as the associated manufacturing and commercialization of diagnostic products. A major institutional turning point came in September 2019, when Hotgen was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. The listing gave the company a public-market identity under ticker 688068.SH and placed it among China’s publicly traded technology-oriented medical companies. Hotgen was later included in the STAR 50 Index, although it was subsequently no longer a constituent. The COVID-19 pandemic significantly changed the company’s visibility and product mix. Hotgen developed 2019-nCoV antigen diagnostic products as governments and healthcare systems sought rapid testing methods that could be used outside centralized laboratories. European regulatory and market developments followed: the company’s COVID-19 antigen products obtained CE certification, and its antigen self-test products gained market access in Germany in early 2021. During the same period, the company’s market capitalization exceeded RMB 10 billion. The pandemic-related testing cycle also coincided with a substantial increase in reported profitability in 2021, when net profit exceeded RMB 2.3 billion according to the referenced account. Hotgen continued pursuing regulatory access in additional markets during 2022. Its rapid antigen testing products were approved by China’s National Medical Products Administration in March. In November, the FDA issued an Emergency Use Authorization for the Hotgen COVID-19 Antigen Home Test. The products were also used in Hong Kong’s public-health response: Hotgen rapid antigen kits were distributed free to the public by the Hong Kong government during 2022. The company’s international activity has not been limited to pandemic products. Hotgen established market presences in countries including the United Kingdom, France, and Germany, and has used international medical-device events to support professional visibility and commercial contacts. Its participation in MEDICA in Düsseldorf in November 2023 was one such publicized event. Hotgen’s broader identity remains that of an in-vitro diagnostics manufacturer rather than solely a COVID-19 test developer. Its continuing scope includes diagnostic reagents, instruments, immunoassay-related products, and molecular diagnostics. The pandemic accelerated its international recognition and temporarily expanded demand for rapid tests, while the company’s longer-term business depends on its wider diagnostic portfolio, regulatory capabilities, manufacturing base, and access to clinical and laboratory markets.

1. 2023MEDICA participation

   Hotgen attended the MEDICA trade fair in Düsseldorf, Germany.

   Source
2. 2022Chinese regulatory approval for rapid antigen products

   Hotgen’s rapid antigen testing products received approval from China’s National Medical Products Administration.

   Source
3. 2022FDA authorization for home test

   The Hotgen COVID-19 Antigen Home Test received United States FDA Emergency Use Authorization.

   Source
4. 2021German market access for COVID-19 self-test

   Hotgen’s COVID-19 antigen self-test products gained market access in Germany.

   Source
5. 2019STAR Market listing

   Hotgen went public on the Shanghai Stock Exchange’s Science and Technology Innovation Board under ticker 688068.SH.

   Source
6. 2005Company founded

   Hotgen Biotech was established in Beijing by Lin Changqing.

   Source

A technology-focused Chinese in-vitro diagnostics manufacturer serving clinical, laboratory, point-of-care, and public-health testing needs.

• In-vitro diagnostic reagentsClinical diagnostics

  Reagent products form the core of Hotgen’s business. They are designed for laboratory, clinical, and near-patient diagnostic workflows in which biological samples are analyzed outside the body. The company’s stated scope includes immunodiagnostic and molecular-diagnostic applications.

• Diagnostic instrumentsMedical diagnostic equipment

  Hotgen manufactures diagnostic instruments used with or alongside in-vitro diagnostic assays. These instruments support the processing, measurement, or interpretation of diagnostic tests and extend the company’s offering beyond standalone reagents.

• 2019-nCoV rapid antigen diagnostic productsRapid infectious-disease testing2020

  During the COVID-19 pandemic, Hotgen developed rapid antigen products for detection of SARS-CoV-2-related infection. The products were intended to provide faster testing than centralized laboratory workflows and obtained regulatory or market access in several jurisdictions.

• Hotgen COVID-19 Antigen Home TestHome diagnostic test2022

  The Hotgen COVID-19 Antigen Home Test is a self-test product designed for home use. It received FDA Emergency Use Authorization in November 2022 after the company had pursued European and Chinese market access for related rapid-antigen products.

• 2023MEDICA Düsseldorf participation

  Germany · International

  Hotgen exhibited or participated at MEDICA in Düsseldorf, one of the major international medical-technology trade fairs, to support professional visibility and engagement with overseas markets.

  Outcome. The company’s participation demonstrated continuing international commercial and industry outreach; specific sales outcomes were not provided.

  Source

• 2020Expansion into COVID-19 antigen testingProduct launch

  The pandemic created demand for rapid diagnostic products that could supplement laboratory-based testing.

  What changed. Hotgen developed and commercialized 2019-nCoV antigen diagnostic products and pursued international regulatory and market access.

  Aftermath. Related products obtained European CE certification and subsequently gained access in Germany, China, the United States, and other public-health settings described in the reference material.

  Source
• 2019Public listing on the STAR MarketOther

  Hotgen sought access to public capital and the technology-focused market for companies listed on the Shanghai Stock Exchange.

  What changed. The company completed its listing on the Science and Technology Innovation Board under ticker 688068.SH.

  Aftermath. The listing established Hotgen as a publicly traded Chinese diagnostics company. No further outcome is specified in the reference material.

  Source

• 2023Hotgen attended MEDICA in Düsseldorf

  The company participated in the MEDICA medical-technology trade fair in Düsseldorf, Germany, highlighting its international market engagement.

  Campaign
  Source
• 2022China approved Hotgen rapid antigen products

  Hotgen’s rapid antigen testing products received approval from China’s National Medical Products Administration.

  RegulationProduct launch
  Source
• 2022Hotgen COVID-19 Antigen Home Test received FDA Emergency Use Authorization

  The United States Food and Drug Administration granted Emergency Use Authorization to the Hotgen COVID-19 Antigen Home Test.

  RegulationProduct launch
  Source
• 2022Hotgen rapid antigen kits distributed in Hong Kong

  Hotgen rapid antigen test kits were distributed free of charge to the public by the Hong Kong government as part of pandemic testing measures.

  Other
  Source
• 2021Hotgen COVID-19 antigen self-test gained market access in Germany

  The company’s COVID-19 antigen self-test products gained access to the German market during the early expansion of European rapid-testing programs.

  Product launchRegulation
  Source
• 2021Hotgen’s market capitalization exceeded RMB 10 billion

  Hotgen’s market capitalization surpassed RMB 10 billion during the pandemic-driven expansion of diagnostic-testing demand.

  Other
  Source
• 2019Hotgen Biotech listed on the Shanghai Stock Exchange STAR Market

  Hotgen Biotech completed its public listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange under ticker 688068.SH.

  Other
  Source

1. Hotgen Biotech